Immunogenicity of the Conjugate Meningococcal ACWY-TT Vaccine in Children and Adolescents Living with HIV

Background: Children and adolescents living with HIV (CALHIV) are at high risk of meningococcal infections and may present lower immune responses to vaccines. The objectives of this study were to assess the immunogenicity of the quadrivalent Men ACWY-TT vaccine (Nimenrix®) in CALHIV after a two-dose...

Descripción completa

Detalles Bibliográficos
Autores: Berzosa, Arantxa, Guillen, Sara, Epalza, Cristina, Escosa, Luis, Navarro, Maria Luisa, Prieto, Luis M, Sainz, Talia, Jimenez de Ory, Santiago, Montes Mota, Marina, Abad, Raquel, Vazquez-Moreno, Julio Alberto, Serrano García, Irene, Ramos-Amador, José Tomás
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/26579
Acceso en línea:https://hdl.handle.net/20.500.12105/26579
Access Level:acceso abierto
Palabra clave:HIV
Men ACWY-TT vaccines
Meningococcal infection
Vaccine response
id ES_19fea3eea26cfeeaddc58885a2287fbc
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/26579
network_acronym_str ES
network_name_str España
repository_id_str
spelling Immunogenicity of the Conjugate Meningococcal ACWY-TT Vaccine in Children and Adolescents Living with HIVBerzosa, ArantxaGuillen, SaraEpalza, CristinaEscosa, LuisNavarro, Maria LuisaPrieto, Luis MSainz, TaliaJimenez de Ory, SantiagoMontes Mota, MarinaAbad, RaquelVazquez-Moreno, Julio AlbertoSerrano García, IreneRamos-Amador, José TomásHIVMen ACWY-TT vaccinesMeningococcal infectionVaccine responseBackground: Children and adolescents living with HIV (CALHIV) are at high risk of meningococcal infections and may present lower immune responses to vaccines. The objectives of this study were to assess the immunogenicity of the quadrivalent Men ACWY-TT vaccine (Nimenrix®) in CALHIV after a two-dose schedule and to describe possible HIV-related factors that may affect the immunogenic response. Methods: A multicenter prospective study was designed, including CALHIV followed in five hospitals in Madrid, between 2019 and 2021. Two doses of the Men ACWY-TT vaccine were administered. Serum bactericidal antibody (SBA) assays using rabbit complement (rSBA) against serogroups C, W, and Y were used to determine seroprotection and vaccine response (the proportion achieving a putative protective titer of ≥eight or a ≥four-fold rise in titer from baseline). Serum was collected at baseline, and at 3 and 12 months after vaccination. Results: There were 29 CALHIV included, 76% of whom were perinatally infected. All were receiving TAR and presented a good immunovirological and clinical status overall. At baseline, 45% of CALHIV had seroprotective titers to at least one serogroup, with individual seroprotection rates of 24%, 28%, and 32% against C, W, and Y, respectively. After a two-dose schedule, vaccine response was 83% for each serogroup, eliciting a vaccine response to all serogroups in 69% of them. One year after vaccination, 75% of CALHIV maintained seroprotective titers against the C serogroup, and 96% against W and Y. None of the HIV-related characteristics analyzed could predict vaccine response or antibody duration. Conclusions: CALHIV who received effective TAR and presented a good immuno-virological situation achieved an appropriate vaccine response after two doses of the Men ACWY-TT vaccine, and antibody-mediated protection against serogroups C, W, and Y was maintained in more than 70% of the patients one year after vaccination.Multidisciplinary Digital Publishing Institute (MDPI)Fundación Familia AlonsoRETICS-Sida (RIS-ISCIII) (España)Instituto de Salud Carlos IIICentro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas)European Society for Paediatric Infectious Diseases20252025-03-2620242024-01-0120242024-01-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.12105/26579reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)InglésengES RD06 0006ES RD06 0006ES CB21 13open accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/265792026-06-12T12:43:37Z
dc.title.none.fl_str_mv Immunogenicity of the Conjugate Meningococcal ACWY-TT Vaccine in Children and Adolescents Living with HIV
title Immunogenicity of the Conjugate Meningococcal ACWY-TT Vaccine in Children and Adolescents Living with HIV
spellingShingle Immunogenicity of the Conjugate Meningococcal ACWY-TT Vaccine in Children and Adolescents Living with HIV
Berzosa, Arantxa
HIV
Men ACWY-TT vaccines
Meningococcal infection
Vaccine response
title_short Immunogenicity of the Conjugate Meningococcal ACWY-TT Vaccine in Children and Adolescents Living with HIV
title_full Immunogenicity of the Conjugate Meningococcal ACWY-TT Vaccine in Children and Adolescents Living with HIV
title_fullStr Immunogenicity of the Conjugate Meningococcal ACWY-TT Vaccine in Children and Adolescents Living with HIV
title_full_unstemmed Immunogenicity of the Conjugate Meningococcal ACWY-TT Vaccine in Children and Adolescents Living with HIV
title_sort Immunogenicity of the Conjugate Meningococcal ACWY-TT Vaccine in Children and Adolescents Living with HIV
dc.creator.none.fl_str_mv Berzosa, Arantxa
Guillen, Sara
Epalza, Cristina
Escosa, Luis
Navarro, Maria Luisa
Prieto, Luis M
Sainz, Talia
Jimenez de Ory, Santiago
Montes Mota, Marina
Abad, Raquel
Vazquez-Moreno, Julio Alberto
Serrano García, Irene
Ramos-Amador, José Tomás
author Berzosa, Arantxa
author_facet Berzosa, Arantxa
Guillen, Sara
Epalza, Cristina
Escosa, Luis
Navarro, Maria Luisa
Prieto, Luis M
Sainz, Talia
Jimenez de Ory, Santiago
Montes Mota, Marina
Abad, Raquel
Vazquez-Moreno, Julio Alberto
Serrano García, Irene
Ramos-Amador, José Tomás
author_role author
author2 Guillen, Sara
Epalza, Cristina
Escosa, Luis
Navarro, Maria Luisa
Prieto, Luis M
Sainz, Talia
Jimenez de Ory, Santiago
Montes Mota, Marina
Abad, Raquel
Vazquez-Moreno, Julio Alberto
Serrano García, Irene
Ramos-Amador, José Tomás
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Fundación Familia Alonso
RETICS-Sida (RIS-ISCIII) (España)
Instituto de Salud Carlos III
Centro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas)
European Society for Paediatric Infectious Diseases
dc.subject.none.fl_str_mv HIV
Men ACWY-TT vaccines
Meningococcal infection
Vaccine response
topic HIV
Men ACWY-TT vaccines
Meningococcal infection
Vaccine response
description Background: Children and adolescents living with HIV (CALHIV) are at high risk of meningococcal infections and may present lower immune responses to vaccines. The objectives of this study were to assess the immunogenicity of the quadrivalent Men ACWY-TT vaccine (Nimenrix®) in CALHIV after a two-dose schedule and to describe possible HIV-related factors that may affect the immunogenic response. Methods: A multicenter prospective study was designed, including CALHIV followed in five hospitals in Madrid, between 2019 and 2021. Two doses of the Men ACWY-TT vaccine were administered. Serum bactericidal antibody (SBA) assays using rabbit complement (rSBA) against serogroups C, W, and Y were used to determine seroprotection and vaccine response (the proportion achieving a putative protective titer of ≥eight or a ≥four-fold rise in titer from baseline). Serum was collected at baseline, and at 3 and 12 months after vaccination. Results: There were 29 CALHIV included, 76% of whom were perinatally infected. All were receiving TAR and presented a good immunovirological and clinical status overall. At baseline, 45% of CALHIV had seroprotective titers to at least one serogroup, with individual seroprotection rates of 24%, 28%, and 32% against C, W, and Y, respectively. After a two-dose schedule, vaccine response was 83% for each serogroup, eliciting a vaccine response to all serogroups in 69% of them. One year after vaccination, 75% of CALHIV maintained seroprotective titers against the C serogroup, and 96% against W and Y. None of the HIV-related characteristics analyzed could predict vaccine response or antibody duration. Conclusions: CALHIV who received effective TAR and presented a good immuno-virological situation achieved an appropriate vaccine response after two doses of the Men ACWY-TT vaccine, and antibody-mediated protection against serogroups C, W, and Y was maintained in more than 70% of the patients one year after vaccination.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024-01-01
2024
2024-01-01
2025
2025-03-26
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.12105/26579
url https://hdl.handle.net/20.500.12105/26579
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.relation.none.fl_str_mv ES RD06 0006
ES RD06 0006
ES CB21 13
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute (MDPI)
publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute (MDPI)
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404079309979648
score 15,812429

Similares en LA Referencia